Taysha Gene Therapies (TSHA) EBITDA (2019 - 2026)
Taysha Gene Therapies (TSHA) EBITDA from Sep 30, 2019 to Mar 31, 2026. The TTM Taysha Gene Therapies (TSHA) EBITDA is -$131M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Taysha Gene Therapies (TSHA) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +50.43% |
| 3 Years TTM | +0.85% |
| 5 Years TTM | +13.60% |
| All Time TTM | +42.09% |
Annual EBITDA change of Taysha Gene Therapies (TSHA)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$43M | -60.50% |
| 2025 | -$109M | +21.22% |
| 2024 | -$90M | +26.93% |
| 2023 | -$71M | -55.93% |
| 2022 | -$161M | -6.66% |
| 2021 | -$173M | +301.88% |
| 2020 | -$43M | +3772.97% |
| 2019 | -$1.11M | N/A |
Comparison Taysha Gene Therapies (TSHA) five years EBITDA CAGR with competitors
Taysha Gene Therapies (TSHA) five years EBITDA CAGR is 13.60%.